Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

Jason Yeung; Tian Wang; Pei Yong Shi

doi:10.1016/j.coviro.2023.101347

Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

Jason Yeung, Tian Wang, Pei Yong Shi

Research output: Contribution to journal › Review article › peer-review

Abstract

The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.

Original language	English (US)
Article number	101347
Journal	Current Opinion in Virology
Volume	62
DOIs	https://doi.org/10.1016/j.coviro.2023.101347
State	Published - Oct 2023

ASJC Scopus subject areas

Virology

Access to Document

10.1016/j.coviro.2023.101347

Cite this

@article{f13e6af7cf4448978f1ac134f508550b,

title = "Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine",

abstract = "The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.",

author = "Jason Yeung and Tian Wang and Shi, {Pei Yong}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = oct,

doi = "10.1016/j.coviro.2023.101347",

language = "English (US)",

volume = "62",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

AU - Yeung, Jason

AU - Wang, Tian

AU - Shi, Pei Yong

PY - 2023/10

Y1 - 2023/10

N2 - The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.

AB - The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.

UR - http://www.scopus.com/inward/record.url?scp=85168441973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168441973&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2023.101347

DO - 10.1016/j.coviro.2023.101347

M3 - Review article

C2 - 37604085

AN - SCOPUS:85168441973

SN - 1879-6257

VL - 62

JO - Current Opinion in Virology

JF - Current Opinion in Virology

M1 - 101347

ER -

Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this